noroxymorphone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

noroxymorphone: an opioid for spinal analgesia; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	5497189
CHEBI ID	187724
SCHEMBL ID	136548
MeSH ID	M0518445

Synonyms (28)

Synonym
morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy- (8ci)
morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-, (5alpha)- (9ci)
en 3169
7,8-dihydro-14-hydroxynormorphinone
morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-, (5alpha)-
33522-95-1
14-hydroxydihydronormorphinone
(5alpha)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
(5.alpha.)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
nor oxymorphone
CHEBI:187724
(4r,4as,7ar,12bs)-4a,9-dihydroxy-1,2,3,4,5,6,7a,13-octahydro-4,12-methanobenzouro[3,2-e]isoquinolin-7-one
noroxymorphone
einecs 251-561-5
unii-9nz7111a9o
9nz7111a9o ,
SCHEMBL136548
en-3169
noroxymorphone [usp impurity]
noroxymorphone [who-dd]
naloxone hydrochloride dihydrate impurity a [ep impurity]
(-)-noroxymorphone
morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-, (5.alpha.)-
HLMSIZPQBSYUNL-IPOQPSJVSA-N
4,5alpha-epoxy-3,14-dihydroxy morphinan-6-one
Q25102255
DTXSID80955145
(4R,4AS,7AR,12BS)-4A,9-DIHYDROXY-2,3,4,4A,5,6-HEXAHYDRO-1H-4,12-METHANOBENZOFURO[3,2-E]ISOQUINOLIN-7(7AH)-ONE

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" There were no significant sex-related differences in any of the pharmacokinetic parameters."	( Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Aantaa, R; Kuusniemi, K; Liukas, A; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Virolainen, P, 2011)	0.37
"The aim of this study is to evaluate the pharmacokinetic profile of oxycodone and three of its metabolites, noroxycodone, oxymorphone and noroxymorphone after intravenous administration in Chinese patients with pain."	( Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. Dong, RH; Gao, HZ; Hao, GT; Li, YY; Liang, YG; Liu, ZY; Qu, HY; Wang, XF; Zhang, LJ; Zhou, HY, 2014)	0.6
"Pharmacokinetic parameters showed that mean values of C(max), AUC(0-t) and AUC(0-∞) of oxycodone were dose dependent, whereas Tmax and t(1/2) were not."	( Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. Dong, RH; Gao, HZ; Hao, GT; Li, YY; Liang, YG; Liu, ZY; Qu, HY; Wang, XF; Zhang, LJ; Zhou, HY, 2014)	0.4
" Preterm neonates were found to have the highest pharmacokinetic variability out of the study population."	( Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine. Hautajärvi, H; Heikkinen, M; Hokkanen, J; Kokki, H; Kokki, M; Pitkänen, H; Ranta, VP; Sankilampi, U; Välitalo, P, 2017)	0.46
"Oxycodone elimination is slower and pharmacokinetic variability more pronounced in neonates when compared to older infants."	( Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine. Hautajärvi, H; Heikkinen, M; Hokkanen, J; Kokki, H; Kokki, M; Pitkänen, H; Ranta, VP; Sankilampi, U; Välitalo, P, 2017)	0.46
" The pharmacokinetics including the relatively short half-life of oxycodone in patients with ESRD with or without haemodialysis and the absence of unconjugated active metabolites indicate that oxycodone can be used at usual doses in patients requiring dialysis."	( Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. Amico, P; Dickenmann, M; Duthaler, U; Hammann, F; Haschke, M; Jehle, AW; Kalbermatter, S; Krähenbühl, S; Lenherr, C; Leuppi-Taegtmeyer, A; Liechti, ME; Meyer Zu Schwabedissen, HE; Schmid, Y, 2019)	0.51

Dosage Studied

Excerpt	Relevance	Reference
"Haemodialysis performed 6-10 h after dosing removed ∼10% of the administered dose of oxycodone predominantly as unconjugated oxycodone and noroxycodone or conjugated oxymorphone and noroxymorphone."	( Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. Amico, P; Dickenmann, M; Duthaler, U; Hammann, F; Haschke, M; Jehle, AW; Kalbermatter, S; Krähenbühl, S; Lenherr, C; Leuppi-Taegtmeyer, A; Liechti, ME; Meyer Zu Schwabedissen, HE; Schmid, Y, 2019)	0.71

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
phenanthrenes	Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (22)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (9.09)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (22.73)	29.6817
2010's	14 (63.64)	24.3611
2020's	1 (4.55)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	39.66 (24.57)
Research Supply Index	3.33 (2.92)
Research Growth Index	4.66 (4.65)
Search Engine Demand Index	53.70 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (39.66)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (12.50%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (4.17%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
acetic acid Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.	2.04	1	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
cyclopropane cyclopropane : A cycloalkane composed of three carbon atoms to form a ring.	7.04	1	0	cycloalkane; cyclopropanes	inhalation anaesthetic
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.13	1	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.13	1	0	metal allergen; nickel group element atom; platinum group metal atom
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	1.94	1	0
oxazolidine oxazolidine: structure given in first source	7.13	1	0	oxazolidine
buprenorphine Buprenorphine: A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.. buprenorphine : A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. It is highly effective for the treatment of opioid use disorder and is also increasingly being used in the treatment of chronic pain.	7.45	2	0	morphinane alkaloid	delta-opioid receptor antagonist; kappa-opioid receptor antagonist; mu-opioid receptor agonist; opioid analgesic
nadp [no description available]	2.25	1	0
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	4.37	4	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxycodone Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.	12.32	14	3	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
oxymorphone Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)	6.86	13	2	morphinane alkaloid
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	3.03	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	8.39	2	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
noroxycodone noroxycodone: RN given for (5alpha)-isomer; metabolite of oxycodone	11.11	10	3	phenanthrenes
morphinans Morphinans: Compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes. They include some of the OPIOIDS found in PAPAVER that are used as ANALGESICS.	8.17	22	3	isoquinoline alkaloid fundamental parent; morphinane alkaloid

Condition	Relationship Strength	Studies	Trials
Chronic Kidney Failure [description not available]	3.97	2	1
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	3.97	2	1
Ache [description not available]	2.1	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.1	1	0
Chronic Illness [description not available]	2.15	1	0
Pain, Chronic [description not available]	3.42	2	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.15	1	0
Chronic Pain Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.	3.42	2	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.05	1	0
Acute Post-operative Pain [description not available]	3.45	1	1
Pain, Postoperative Pain during the period after surgery.	3.45	1	1
Benign Neoplasms [description not available]	2.99	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.99	1	0

chemdatabank.com